AU Patent

AU2013231191B2 — Prolyl hydroxylase inhibitors

Assigned to GlaxoSmithKline LLC · Expires 2015-09-03 · 11y expired

What this patent protects

C:\Users\xd\AppData\Local\Microsoft\Windows\Temporary Internet Files\Content.Word\-WRCI 948.tnp-24/09/2013 The invention described herein relates to certain pyrimidinetrione N-substituted glycine derivatives of formula (I), which are antagonists of HIF prolyl hydroxylases and are…

USPTO Abstract

C:\Users\xd\AppData\Local\Microsoft\Windows\Temporary Internet Files\Content.Word\-WRCI 948.tnp-24/09/2013 The invention described herein relates to certain pyrimidinetrione N-substituted glycine derivatives of formula (I), which are antagonists of HIF prolyl hydroxylases and are useful for treating diseases benefiting from the inhibition of this enzyme, anemia being one example. 4 2 R N N R

Drugs covered by this patent

Patent Metadata

Patent number
AU2013231191B2
Jurisdiction
AU
Classification
—
Expires
2015-09-03
Drug substance claim
No
Drug product claim
No
Assignee
GlaxoSmithKline LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.